Key facts
- It has raised $1.1M across 1 recorded rounds; the latest was Seed Round ($895K) in Apr 2025.
- Fedora Pharmaceuticals has filed 2 Form Ds with the SEC since 2013, most recently Jun 2025 ($895K sold to 10 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Fedora Pharmaceuticals
Funding rounds
1 roundsAbout Fedora Pharmaceuticals
Developer of novel antimicrobial agents designed to treat multidrug-resistant infections. The company's technology includes a beta-lactamase inhibitor that selectively and effectively inhibits beta-lactamases, and restores the activity of the antibiotics, enabling the healthcare industry to boost antibiotic development to address antimicrobial resistance.
- Sector
- Healthcare
- HQ
- Edmonton, Canada
- Founded
- 2012
- Employees
- 5
- Website
- fedorapharma.com/
- Ownership
- Privately Held (backing)
Fedora Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Fedora Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Fedora Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.